KCT0003069招募中未知
A phase III, randomized, multi-center study to determine the efficacy of the intercalating combination treatment of chemotherapy and gefitinib or chemotherapy as adjuvant treatment in NSCLC with common EGFR mutations.
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 0No Limit（—）
- 性别
- All
入选标准
- •1. Completely resected non-squamous cell NSCLC with stage IIa to IIIb (excluding N3) according to Version 8 of the IASLC Staging Manual in Thoracic Oncology
- •2. Tumors with common EGFR mutations (19del or L858R)
- •3. Adequate oran function
排除标准
- •1. Patients who were exposed to the chemotherapy or EGFR TKIs for NSCLC.
- •2. Patients with interstitial lung disease
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNa2a) in Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 1. ACHIEVE -1 - ACHIEVE-1EUCTR2006-002703-13-ATHuman Genome Sciences, Inc.1,290
进行中（未招募）
1 期
A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNa2a) in Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 1. ACHIEVE -1 - ACHIEVE-1Chronic hepatitis C (CHC) genotype 1.MedDRA version: 8.0 Level: LLT Classification code 10008912EUCTR2006-002703-13-FRHuman Genome Sciences, Inc.
进行中（未招募）
不适用
A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNa2a) in Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 1. ACHIEVE -1 - ACHIEVE-1Chronic hepatitis C (CHC) genotype 1.MedDRA version: 8.0Level: LLTClassification code 10008912EUCTR2006-002703-13-DEHuman Genome Sciences, Inc.1,290
进行中（未招募）
1 期
A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNa2a) in Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 2 or 3. ACHIEVE-2/3 - ACHIEVE-2/3Chronic Hepatitis C (CHC) genotype 2/3.MedDRA version: 8.0 Level: LLT Classification code 10008912EUCTR2006-002704-34-FRHuman Genome Sciences, Inc.
进行中（未招募）
1 期
A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNa2a) in Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 2 or 3. ACHIEVE-2/3Estudio multicéntrico, aleatorizado, de fase 3, dirigido a evaluar la eficacia y seguridad de la albúmina interferón alfa-2b (alb-IFN) combinada con ribavirina en comparación con peginterferón alfa-2a (PEGASYS or peg-IFNa2a) combinado con ribavirina en sujetos con hepatitis C crónica, genotipo 2-3, no tratados anteriormente con interferón alfa. ACHIEVE-2/3 - ACHIEVE-2/3Chronic Hepatitis C (CHC) genotype 2/3.MedDRA version: 8.0Level: LLTClassification code 10008912EUCTR2006-002704-34-ESHuman Genome Sciences, Inc.